By Kristy Dorsey

MEDICAL testing specialist Omega Diagnostics, which has been in the news this month for its work on Covid-19, has signed a deal to supply hundreds of thousands of its HIV tests into lower and middleincome countries around the world.

The agreement with global health organisation Clinton Health Access Initiative (CHAI) will accelerate distribution of Omega’s Visitect CD4 into what the World Bank defines as “eligible countries”. The agreement runs until December 2021, and will lead to the distribution of up to 500,000 CD4 tests.

With support from international development agency Unitaid, CHAI will place an initial order for 100,000 CD4 kits within the next fortnight. Delivery will depend on demand being confirmed by certain eligible countries by the end of June, with shipment to follow thereafter.

READ MORE: Omega Diagnostics surges as virus testing plans progress

CD4 tests are used to assess the progression of HIV and prioritise patients at risk of opportunistic infections. Omega’s kit is currently the only hand-held test of its kind that can provide a reading at the point of care to people living in remote areas, or those where few laboratory resources are available.

“We are pleased that Omega has been able to enter into this supply agreement with CHAI, who have been very supportive towards accelerating the availability of our Visitect CD4 Advanced Disease,” chief executive Colin King said.

“This test will help support the healthcare needs of the many people in those countries that are most in need.”

The CD4 tests are made at Omega’s headquarters in Alva, where the company is also looking at ways to increase capacity for the production of at-home tests for Covid-19 antibodies. That diagnostic is currently in development by the UK Rapid Test Consortium (RTC), which includes Omega, Oxford University, BBI Solutions and CIGA Healthcare, and is led by Abingdon Health.

READ MORE: Omega Diagnostics gears up for mass roll-out of virus testing kits

Omega is also involved in a second coronavirus partnership with Bedfordshire-based Mologic, under which the Scottish company will produce Mologic’s test kits at its facility in Littleport, Cambridgeshire.

The pair announced earlier this week that their lab-based test has received the CE Mark required for sales into Europe. They are now awaiting validation from Public Health England and NHS Scotland before ramping up production of as many as 46,000 tests per day. A decision is expected imminently